SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Johnny Cash — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohnny Cash
Date of birth1932-02-26
IdentifiersMRN HR-ML004-SYN-TD; SSN (made up) 000-04-8125
Document date2003-08-14
AuthorGideon Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month diabetes review with glaucoma imaging. [S]

History of Present Illness

Mr. Cash returns for his six-month review. Since midodrine was raised to 5 mg he rarely feels lightheaded, only if he stands quickly after lunch, and he has had no falls. He finished physical therapy and does the home exercises most days. The low-vision therapist reviewed his home lighting, and a second stair handrail is in place. His fasting home readings run 110 to 140 mg/dL, with none below 70. He has no scalp tingling or trouble passing urine and takes the last midodrine by mid-afternoon. He uses both eye drops daily and notices no change in his vision. The FIT kit from the wellness visit has not been returned. [S]

ElementDetail
Interval changeRarely lightheaded on midodrine 5 mg; no falls
Home glucoseFasting 110 to 140 mg/dL; none below 70
RehabilitationPhysical therapy finished; home exercises; second stair handrail fitted
VisionNo change noticed
Open itemsFIT kit not returned

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight down 1 kg; no fever
EyesPositiveTunnel vision, unchanged; no eye pain
CardiovascularNegativeNo fainting; lightheaded only on standing quickly after lunch
RespiratoryNegativeNo cough or breathlessness
GenitourinaryNegativeNo difficulty passing urine
EndocrineNegativeNo symptoms of low glucose

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 500 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2001-05-06 to 2003-02-27completedS
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2003-02-27activeS
Sitagliptin 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2003-03-27activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2003-02-27activeS
Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtimeOne drop in each eye at bedtimeOphthalmic route2000-09-11activeS
Dorzolamide 2% ophthalmic solution, one drop in each eye twice dailyOne drop in each eye twice dailyOphthalmic route2003-02-27activeS
Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2003-03-27 to 2003-05-29completedS
Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2003-05-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2003-08-14Body height188cmS
2003-08-14Body weight92.5kgS
2003-08-14Body mass index (BMI) [Ratio]26.2kg/m2S
2003-08-14Systolic blood pressure134mm[Hg]S
2003-08-14Diastolic blood pressure74mm[Hg]S
2003-08-14Heart rate72/minS
2003-08-14Respiratory rate16/minS
2003-08-14Body temperature36.6CelS
2003-08-14Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2003-08-14Hemoglobin A1c/Hemoglobin.total in Blood7.3%<=5.6%HighS
2003-08-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2003-08-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2003-08-14Creatinine [Mass/volume] in Serum or Plasma1.05mg/dL0.74-1.35 mg/dLNormalS
2003-08-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M73mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2003-08-14Glucose [Mass/volume] in Serum or Plasma131mg/dL70-99 mg/dLHighS
2003-08-14Albumin/Creatinine [Mass Ratio] in Urine16mg/g<=30 mg/gNormalS
2003-08-14Right eye Intraocular pressure14mm[Hg]10-21 mmHgNormalS
2003-08-14Left eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2003-08-14Right retina Retinal nerve fiber layer.mean thickness by OCT60um80-120 umLowS
2003-08-14Left retina Retinal nerve fiber layer.mean thickness by OCT57um80-120 umLowS
2003-08-14Visual acuity best corrected Right eye by ETDRS eye chart68{letters}>=80LowS
2003-08-14Visual acuity best corrected Left eye by ETDRS eye chart62{letters}>=80LowS

Physical Exam

Vital signs recorded on 2003-08-14; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and well; walks with a cane
EyesEye clinic today: pressure 14 mmHg right and 15 mmHg left; best-corrected acuity 68 letters right and 62 left; optic nerve appearance unchanged from intake
CardiovascularRegular rhythm; blood pressure 148/82 mmHg lying, 134/74 mmHg seated, and 120/70 mmHg after three minutes standing, without symptoms
FeetSkin intact; no ulcers or calluses; sensory loss to the ankles unchanged; pedal pulses present

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intakeactiveconfirmed E11.43S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy.
Neurogenic orthostatic hypotension from diabetic autonomic neuropathyactiveconfirmed I95.1S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome.
Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feetactiveconfirmed E11.42S — Synthetic finding linked to his description of numb lower extremities.
Primary open-angle glaucoma, both eyes, severe stageactiveconfirmed H40.1133S — Synthetic modern diagnosis; the type and stage are not documented historically.
Mild nonproliferative diabetic retinopathy without macular edema, both eyesactiveconfirmed E11.3293S — Synthetic finding from the dilated eye examination.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
History of recurrent pneumoniaactiveconfirmed Z87.01S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHbA1cEvery 3 months until at goal or after a therapy change; every 6 months when stableCompleted today7.3%, at goal; repeat every six months
LaboratoryBasic metabolic panel and urine albumin-creatinine ratioYearly when eGFR is 60 or more and albumin is normalCompleted todayeGFR 73; potassium 4.5; urine albumin-creatinine ratio 16 mg/g. Repeated at six months because he takes full-dose metformin and midodrine, which the kidney clears
LaboratoryLipid panelEvery 3 to 12 months until stable, then yearlyDueLDL 74 three months ago; at the annual review with lipoprotein(a)
LaboratoryVitamin B12 on metforminPeriodically on long-term metformin, especially with neuropathyDue286 pg/mL at intake, low-normal with neuropathy; repeat at the annual review, with methylmalonic acid if still below 300
LaboratoryALT, AST, and platelets for FIB-4At diagnosis and yearlyDueAST and a platelet count added to the annual tests after the gap noted at three months
ExaminationBlood pressure, weight, and BMIEvery visitCompleted todaySeated 134/74 mmHg; weight 92.5 kg, down 3.5 kg since intake
ExaminationLying, seated, and standing blood pressureEvery visitCompleted todayLying 148/82, standing 120/70 mmHg; goal of a standing systolic pressure of 100 or more met
ExaminationFoot examination (inspection, pulses, monofilament)Every visit with loss of protective sensationCompleted todayNo ulcer; sensory loss unchanged
ExaminationDental examinationYearlyDueNo dental examination on record; advised to see his dentist
ExaminationTonometry (eye pressure)Every visitCompleted today14 mmHg right and 15 mmHg left
ExaminationBest-corrected visual acuityEach comprehensive eye examinationCompleted today68 letters right and 62 left, against 68 and 63 at intake
ExaminationDrop adherence, ocular surface, and systemic effects of glaucoma dropsEvery visitCompleted todayBoth drops used daily; no ocular surface irritation; no systemic effect
ImagingOCT of the optic nerve and nerve fiber layerEvery 6 to 12 months; every 6 months in severe glaucomaCompleted today60 µm right and 57 µm left, against 61 and 57 at intake: no structural progression
SurveyVisual field (Humphrey 24-2)Every 6 to 12 monthsCompleted todayNo new defect against intake
SurveyVisual field (Humphrey 10-2)In advanced disease, alongside the 24-2DeferredNot done at intake or today, a deviation from the protocol for severe glaucoma. The 24-2 and OCT are stable, so loss near fixation is unlikely to have been missed; the eye clinic will add a 10-2 at the next field visit
ExaminationGonioscopy and corneal thicknessAt the initial evaluation; repeat only with an unexplained pressure changeNot indicatedBaseline measures belong to the eye clinic's initial evaluation; the pressure response has been as expected
SurveyHypoglycemia review and home glucose logEvery visitCompleted todayNo readings below 70 mg/dL
SurveyDiabetes distress, anxiety (GAD-7), disordered eating, and social needs screensYearlyDueNot yet done this year; at the annual review
SurveyCognitive screen and fall riskYearly at 65 or olderUp to dateMini-Cog 5 of 5 at intake; Timed Up and Go 14 seconds at the wellness visit
Survey10-year cardiovascular risk (PREVENT)Yearly from 40 to 75 without cardiovascular diseaseNot indicatedHe already takes a high-intensity statin for diabetes with complications, so the score would not change treatment
SurveyTobacco useEvery visitCompleted todayNo tobacco use
Medication safetyMidodrine safety: lying pressure, timing, and urinary retentionEvery visit on midodrineCompleted todayLying 148/82 mmHg; no retention
Medication safetyVaccination reviewYearly, and as doses fall dueDueRecombinant zoster dose 2 is due within six months of dose 1, at his pharmacy, alongside the seasonal influenza vaccine; RSV and COVID-19 before the respiratory season; tetanus booster
ReferralDiabetes self-management education and medical nutrition therapyAt diagnosis, yearly, with new complications, and at care transitionsReferredNot arranged in the first six months despite two medication changes, a deviation from the protocol. No harm resulted, since HbA1c reached goal without hypoglycemia. Referred today to an individual program with large-print materials because of his vision
Self-managementExercise, diet, orthostatic measures, and foot self-careEvery visitCompleted todayHome exercises most days; smaller lunches; daily foot checks

Goal progress:

Guideline basis: Standards of Care in Diabetes—2025 (2025); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026)

Follow-up: Eye clinic review in three to six months. Diabetes review in six months with HbA1c. Annual review with lipids, lipoprotein(a), vitamin B12, AST, platelet count, and the yearly screens. [S]